ES2151060T3 - Tratamiento de la hiperexcitacion de las funciones de las celulas nerviosas. - Google Patents

Tratamiento de la hiperexcitacion de las funciones de las celulas nerviosas.

Info

Publication number
ES2151060T3
ES2151060T3 ES95918244T ES95918244T ES2151060T3 ES 2151060 T3 ES2151060 T3 ES 2151060T3 ES 95918244 T ES95918244 T ES 95918244T ES 95918244 T ES95918244 T ES 95918244T ES 2151060 T3 ES2151060 T3 ES 2151060T3
Authority
ES
Spain
Prior art keywords
functions
treatment
hyperexcitation
sensitive
nervous cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918244T
Other languages
English (en)
Other versions
ES2151060T5 (es
Inventor
Alf Sollevi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Item Development AB
Original Assignee
Item Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2151060(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Item Development AB filed Critical Item Development AB
Publication of ES2151060T3 publication Critical patent/ES2151060T3/es
Application granted granted Critical
Publication of ES2151060T5 publication Critical patent/ES2151060T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION DESCRITA SE REFIERE AL TRATAMIENTO DE FUNCIONES NERVIOSAS SENSITIVAS HIPEREXCITADAS, P. EJ. NEUROPATIA EN HUMANOS, QUE INCLUYE LA ADMINISTRACION PARENTERAL DE UNA CANTIDAD DE UN AGONISTA DEL RECEPTOR DE ADENOSINA A DICHOS INDIVIDUOS. SE HA DEMOSTRADO QUE UN AGONISTA DEL RECEPTOR DE ADENOSINA PUEDE ALIVIAR O NORMALIZAR FUNCIONES NERVIOSAS SENSITIVAS HIPEREXCITADAS COMO LA PERCEPCION DEL TACTO, TEMPERATURA, VIBRACION, DOLOR, PRESION Y ALTERACIONES EN OTRAS FUNCIONES SENSITIVAS.
ES95918244T 1994-05-02 1995-04-28 Tratamiento de la hiperexcitacion de la funcion de las celulas nerviosas. Expired - Lifetime ES2151060T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401499A SE9401499D0 (sv) 1994-05-02 1994-05-02 New method of treatment
SE9401499 1994-05-02

Publications (2)

Publication Number Publication Date
ES2151060T3 true ES2151060T3 (es) 2000-12-16
ES2151060T5 ES2151060T5 (es) 2005-06-01

Family

ID=20393856

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918244T Expired - Lifetime ES2151060T5 (es) 1994-05-02 1995-04-28 Tratamiento de la hiperexcitacion de la funcion de las celulas nerviosas.

Country Status (9)

Country Link
US (1) US5691318A (es)
EP (1) EP0799045B2 (es)
JP (1) JP3501460B2 (es)
AU (1) AU2423595A (es)
CA (1) CA2188662C (es)
DE (1) DE69518438T3 (es)
ES (1) ES2151060T5 (es)
SE (1) SE9401499D0 (es)
WO (1) WO1995029680A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US6180616B1 (en) 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
AU4888397A (en) * 1997-09-22 1999-04-12 Item Development Ab New method of treatment
CA2443135C (en) 2001-03-30 2010-07-13 Allan R. Moorman Pharmaceutically active compounds and methods of use
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
EP2004139A1 (en) * 2006-03-31 2008-12-24 Adenobio N.V. Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
CN102159209A (zh) * 2008-08-11 2011-08-17 奥克兰联合服务有限公司 听力缺失的治疗
EP2849566B1 (en) * 2012-02-11 2018-04-04 Academia Sinica Adenosine analogues for the treatment of pain
JP6440240B2 (ja) * 2014-02-19 2018-12-19 国立大学法人富山大学 末梢神経障害誘発感覚異常を改善する外用剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2260331B1 (es) * 1974-02-08 1978-01-13 Mauvernay Centre Europ Rech
EP0413751A4 (en) * 1988-05-02 1992-07-22 N. Eric Naftchi Neurologically active compounds
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
DK62592D0 (es) * 1992-05-14 1992-05-14 Novo Nordisk As

Also Published As

Publication number Publication date
DE69518438T2 (de) 2000-12-14
AU2423595A (en) 1995-11-29
DE69518438T3 (de) 2005-10-06
JP3501460B2 (ja) 2004-03-02
EP0799045B2 (en) 2004-12-22
DE69518438D1 (de) 2000-09-21
US5691318A (en) 1997-11-25
CA2188662C (en) 2000-09-05
EP0799045A1 (en) 1997-10-08
WO1995029680A1 (en) 1995-11-09
EP0799045B1 (en) 2000-08-16
JPH09512545A (ja) 1997-12-16
ES2151060T5 (es) 2005-06-01
SE9401499D0 (sv) 1994-05-02

Similar Documents

Publication Publication Date Title
ES2151060T3 (es) Tratamiento de la hiperexcitacion de las funciones de las celulas nerviosas.
AP1411A (en) Pyrrolo[2,3d] pyrimidine compositions and their use.
UY24793A1 (es) Derivados de 8-azabiciclo[3.2.1]octano, 8-azabiciclo[3.2.1]oct-6-eno, 9-azabiciclo[3.3.1]nonano, 9-aza-3-oxabiciclo[3.3.1]nonano y 9-aza-3-tiabiciclo[3.3.1]nonano, su preparación y sus usos como insecticidas.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
MX9303711A (es) Nucleosidos de pirimida sustituida que tienen actividad anti-tumoral y anti-viral y composicion farmaceutica que los contiene.
EA199900553A1 (ru) Чрескожная терапевтическая система
DE60136293D1 (de) Vorrichtung zum abliefern von pharmazeutika an das innenohr
ES2179193T3 (es) Combinaciones sinergicas de zidovudina, 1592u89 y 3tc.
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
AU4881697A (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
PT706385E (pt) Utilizacao de isovaleramida como agente ansiolitico suave e como agente sedativo suave
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
KR900700138A (ko) 위생장치
ATE153244T1 (de) Benutzeraktivierte, iontophoretische vorrichtung
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
Paxton Curing Bodies—Curing Souls: Hrabanus Maurus, Medical Education, and the Clergy in Ninth-Century Francia
NO20005548D0 (no) Mykobakterieinhibitorer
UY24915A1 (es) Derivados de benzoxazindiona, aplicación de los mismos y medicamentos que los contienen
ES2184935T3 (es) Fregadero de cocina.
Harding Uruguay: Resignation Of Three Cabinet Ministers Deepens Government Political Crisis
FR2688003B1 (fr) Derives de nucleosides, leur preparation et leurs applications biologiques.
KR890011425A (ko) 입체 tv 필터기
ATE153027T1 (de) Zuckerderivate von makroliden

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19951204

FG2A Definitive protection

Ref document number: 799045

Country of ref document: ES